Your Voice Is Important

At Praxis, we believe that if families and caregivers are a part of the research and development process it will improve our chances to successfully deliver a potentially disease-modifying treatment to patients with mutations in the SCN2A gene.

FDA Grants Praxis ODD for PRAX-562 for the Treatment of SCN2A-DEE

On Wednesday, April 28, Praxis was granted orphan-drug designation (ODD) by the FDA for PRAX-562 for “treatment of SCN2A developmental and epileptic encephalopathy.”

Thank You SCN2A Community

We would like to extend our sincere gratitude to SCN2A community members who joined us for our virtual community discussions in March. We hope you found the information helpful.

Upcoming SCN2A Virtual Event: An introduction to Praxis, exploring potential treatments for the SCN2A community

Like you, we at Praxis Precision Medicines (Praxis) envision a future where there is greater understanding of SCN2A-related gene mutations and better treatments to help the children and families affected by this rare disorder.

Praxis and The Florey Institute Collaborate on Innovative SCN2A Research

Exciting news for the SCN2A community! Praxis has recently entered into an innovative research collaboration with The Florey Institute of Neuroscience and Mental Health.

Honoring International SCN2A Awareness Day

At Praxis, we honor International #SCN2A Awareness Day and remain committed to providing therapies for patients as efficiently as possible.

Praxis Precision Medicines Partners With Ciitizen To Improve Patient-Guided Drug Development 

Innovative collaboration to be implemented across multiple indications starting with SCN2A-DEE